Fox Chase Cancer Center | Strategic Alliance Partners

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

It is often said that one person can make a difference, but it is also evident that when we band together, we can achieve greatness.

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Fox Chase Cancer Center was recognized by the ECOG-ACRIN Cancer Research Group for outstanding achievement in accrual, scientific contribution, and more.

Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference for her work detailing the mychoice digital health tool.

Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms.

Edna “Eti” Cukierman, PhD, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Alexander Kutikov, MD, FACS, chair of the Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, will receive the Andrew C. Novick Award from the Kidney Cancer Association.

Rebecca Shulman, MD, assistant professor in the Department of Radiation Oncology at Fox Chase Cancer Center, was recently recognized with the Robert A. Winn Diversity in Clinical Trials Career Development Award.

As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells.

Igor Astsaturov, MD, PhD, has been appointed inaugural holder of the Paul F. Engstrom Professorship in Oncology.

Temple Health was recently recognized with the American College of Gastroenterology’s Service Award for Colorectal Cancer Outreach, Prevention & Year-Round Excellence for its coordinated health campaign against colon cancer.

Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.

In a recent study, researchers at Fox Chase Cancer Center demonstrated how amplification and rearrangement of a gene associated with leukemia known as MLL is directly controlled by epigenetic factors, providing needed insights into a new therapeutic opportunity.

Researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University will serve as two of the principal investigators on the Asian American Community Cohort and Equity Study, which is part of a new seven-year epidemiological cohort study of Asian Americans, Native Hawaiians, and Pacific Islanders.

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Melissa Culligan, RN, MS, PhD candidate, director of Thoracic Surgery Research at Temple Health, was recently honored with the International Association for the Study of Lung Cancer’s Lectureship Award for Nurses and Allied Health Professionals.